Assessing the impact of sex on high-frequency repetitive transcranial magnetic stimulation´s clinical response in schizophrenia - results from a secondary analysis.

RESIS negative symptoms rTMS schizophrenia sex

Journal

The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry
ISSN: 1814-1412
Titre abrégé: World J Biol Psychiatry
Pays: England
ID NLM: 101120023

Informations de publication

Date de publication:
01 May 2024
Historique:
pubmed: 17 3 2024
medline: 17 3 2024
entrez: 17 3 2024
Statut: aheadofprint

Résumé

The evidence for repetitive transcranial magnetic stimulation (rTMS) to treat negative symptoms in schizophrenia (SCZ) is increasing, although variable response rates remain a challenge. Subject´s sex critically influences rTMS´ treatment outcomes. Females with major depressive disorder are more likely to respond to rTMS, while SCZ data is scarce. Using data from the 'rTMS for the Treatment of Negative Symptoms in Schizophrenia' (RESIS) trial we assessed the impact of sex on rTMS´ clinical response rate from screening up to 105 days after intervention among SCZ patients. The impact of resting motor threshold (RMT) on response rates was also assessed. 157 patients received either active or sham rTMS treatment. No significant group differences were observed. Linear mixed model showed no effects on response rates (all In the largest rTMS trial on the treatment of SCZ negative symptoms we did not observe any significant effect of sex on treatment outcomes. Better assessments of sex-related differences could improve treatment individualisation.

Sections du résumé

BACKGROUND UNASSIGNED
The evidence for repetitive transcranial magnetic stimulation (rTMS) to treat negative symptoms in schizophrenia (SCZ) is increasing, although variable response rates remain a challenge. Subject´s sex critically influences rTMS´ treatment outcomes. Females with major depressive disorder are more likely to respond to rTMS, while SCZ data is scarce.
METHODS UNASSIGNED
Using data from the 'rTMS for the Treatment of Negative Symptoms in Schizophrenia' (RESIS) trial we assessed the impact of sex on rTMS´ clinical response rate from screening up to 105 days after intervention among SCZ patients. The impact of resting motor threshold (RMT) on response rates was also assessed.
RESULTS UNASSIGNED
157 patients received either active or sham rTMS treatment. No significant group differences were observed. Linear mixed model showed no effects on response rates (all
CONCLUSION UNASSIGNED
In the largest rTMS trial on the treatment of SCZ negative symptoms we did not observe any significant effect of sex on treatment outcomes. Better assessments of sex-related differences could improve treatment individualisation.

Identifiants

pubmed: 38493362
doi: 10.1080/15622975.2024.2327028
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1-9

Auteurs

Mattia Campana (M)

Department of Psychiatry and Psychotherapy, LMU University Hospital Munich, Munich, Germany.

Thomas Schneider-Axmann (T)

Department of Psychiatry and Psychotherapy, LMU University Hospital Munich, Munich, Germany.

Thomas Wobrock (T)

Department of Psychiatry and Psychotherapy, University Medical Center Göttingen, Goettingen, Germany.
County Hospitals Darmstadt-Dieburg, Groß-Umstadt, Germany.

Berend Malchow (B)

Department of Psychiatry and Psychotherapy, University Medical Center Göttingen, Goettingen, Germany.

Berthold Langguth (B)

Department of Psychiatry and Psychotherapy, University of Regensburg, Regensburg, Germany.

Michael Landgrebe (M)

Department of Psychiatry and Psychotherapy, University of Regensburg, Regensburg, Germany.
Department of Psychiatry, Psychosomatics and Psychotherapy, kbo-Lech-Mangfall-Klinik Agatharied, Germany.

Peter Eichhammer (P)

Department of Psychiatry and Psychotherapy, University of Regensburg, Regensburg, Germany.

Elmar Frank (E)

Department of Psychiatry and Psychotherapy, University of Regensburg, Regensburg, Germany.

Joachim Cordes (J)

Department of Psychiatry and Psychotherapy, Medical Faculty, Heinrich-Heine University, Düsseldorf, Germany.
Department of Psychiatry and Psychotherapy, The Florence-Nightingale-Hospital, Düsseldorf, Germany.

Wolfgang Wölwer (W)

Department of Psychiatry and Psychotherapy, Medical Faculty, Heinrich-Heine University, Düsseldorf, Germany.

Wolfgang Gaebel (W)

Department of Psychiatry and Psychotherapy, Medical Faculty, Heinrich-Heine University, Düsseldorf, Germany.

Georg Winterer (G)

Department of Anesthesiology and Operative Intensive Care Medicine (CCM, CVK), Charité- Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.

Göran Hajak (G)

Department of Psychiatry, Psychosomatics and Psychotherapy, Bamberg, Germany.

Christian Ohmann (C)

European Clinical Research Network (ECRIN), Düsseldorf, Germany.

Pablo E Verde (PE)

Coordination Centre for Clinical Trials, Heinrich-Heine University, Düsseldorf, Germany.

Marcella Rietschel (M)

Department of Genetic Epidemiology in Psychiatry, Institute of Central Mental Health, Medical Faculty Mannheim, University of Heidelberg, Germany.

Raees Ahmed (R)

University Medical Center Goettingen, Goettingen, Germany.

Matin Mortazavi (M)

Deparment of Psychiatry, Psychotherapy and Psychosomatics, Faculty of Medicine, University of Augsburg, Augsburg, Germany.

Wolfgang Strube (W)

Deparment of Psychiatry, Psychotherapy and Psychosomatics, Faculty of Medicine, University of Augsburg, Augsburg, Germany.

Peter Falkai (P)

Department of Psychiatry and Psychotherapy, LMU University Hospital Munich, Munich, Germany.
Max Planck Institute of Psychiatry, Munich, Germany.
DZPG (German Center for Mental Health), Augsburg, Germany.

Alkomiet Hasan (A)

Deparment of Psychiatry, Psychotherapy and Psychosomatics, Faculty of Medicine, University of Augsburg, Augsburg, Germany.
DZPG (German Center for Mental Health), Augsburg, Germany.

Elias Wagner (E)

Deparment of Psychiatry, Psychotherapy and Psychosomatics, Faculty of Medicine, University of Augsburg, Augsburg, Germany.
Evidence-based Psychiatry and Psychotherapy, Faculty of Medicine, University of Augsburg, Augsburg, Germany.

Classifications MeSH